Immune Monitoring and Prognostic / Predictive Biomarkers
Our strategy is to develop immunotherapeutic concepts into early phase I trials and accompany running clinical trials to understand mode of action and mode of resistance. Our particular focus is on close immune monitoring of T cell subsets, NK cells and soluble factors during the course of treatment. Using phenotypic and genotypic characterization of the immune contexture in conjunction with quantification of residual disease is the basis for identifying prognostic and predictive biomarkers.
We aim to understand the evolution of the diseases and the dynamic interaction with the immune system during the course of the disease in relation to applied therapeutic intervention.Close observation of the clinical aspect of the patient with a thorough assessment of static and dynamic parameters will create the basis for improving immunotherapeutic strategies.